A Phase Ia/Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 19 Jun 2025
At a glance
- Drugs Atezolizumab (Primary) ; RO 7759065 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Genentech
Most Recent Events
- 19 Nov 2024 Planned initiation date changed from 31 Oct 2024 to 30 Nov 2024.
- 31 Oct 2024 Planned initiation date changed from 10 Oct 2024 to 31 Oct 2024.
- 20 Sep 2024 Planned initiation date (estimated date of first participant enrollement) changed from 15 Aug 2024 to 10 Oct 2024.